Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
dsm-firmenich AG (DSFIR.AS)
Kaiseraugst, AG, CH
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes, hydrocolloids, cultures, natural colorants, nutritional ingredients, and plant-based proteins. The Health, Nutrition & Care segment provides solutions for the early life nutrition, dietary supplement, pharmaceutical, medical nutrition, biomedical materials, and nutrition improvement markets. This segment also offers vitamins, nutritional lipids, minerals, carotenoids, botanical nutraceuticals, digestive enzymes, postbiotics, probiotics and prebiotics, and active pharmaceutical ingredients; biomedical solutions; and premix, market-ready, and personalized nutrition solutions, as well as expert services in regulatory affairs and nutrition. The Animal Nutrition & Health segment offers animal proteins, vitamins, performance solutions, and data-driven precision services. The company was founded in 1902 and is based in Kaiseraugst, Switzerland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.15% | +1.23% | +13.53% | +19.39% | +1.98% | +4.94% | -26.38% | -30.81% | -38.72% | -38.72% | -38.72% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 11 | 0 |
| Hold | 6 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | -1 |
-
Revenue growth Chemicals - Specialty: +4.7%-29.4% Q4'25: -22.4% (vs Q3'24)
-
EPS growth Chemicals - Specialty: +13.2%-543.6% Q4'25: -1,664.1% (vs Q3'24)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+28.7% Q4'25: +29.6% (vs Q3'24)
-
EBIT margin Chemicals - Specialty: +8.8%+7.9% Q4'25: +2.8% (vs Q3'24)
-
ROIC Chemicals - Specialty: +5.6%+2.4% Q4'25: +1.3% (vs Q3'24)
-
Share dilution Chemicals - Specialty: +0.1%-2.0% ★ Q4'25: -1.4% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×1.47× Q4'25: 18.58× (vs Q3'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 19 Rev. Ana. 17 EPS Ana. |
Dec 2027 19 Rev. Ana. 17 EPS Ana. |
Dec 2028 8 Rev. Ana. 10 EPS Ana. |
Dec 2029 10 Rev. Ana. 13 EPS Ana. |
Dec 2030 16 Rev. Ana. 7 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
10.63B
est: 11.65B (-8.7%)
|
12.80B
est: 12.83B (-0.2%)
|
9.03B
est: 12.59B (-28.2%)
|
9.17B
8.86B – 9.56B
-27.2% YoY
|
9.59B
9.26B – 10.08B
+4.5% YoY
|
10.03B
9.69B – 10.51B
+4.7% YoY
|
10.62B
10.26B – 11.13B
+5.9% YoY
|
10.93B
10.56B – 11.45B
+2.9% YoY
|
| EBITDA |
822.00M
est: 1.29B (-36.3%)
|
561.00M
est: 2.13B (-73.7%)
|
3.85B
est: 2.09B (+84.1%)
|
1.52B
1.47B – 1.59B
-27.2% YoY
|
1.59B
1.54B – 1.68B
+4.5% YoY
|
1.67B
1.61B – 1.75B
+4.7% YoY
|
1.77B
1.71B – 1.85B
+5.9% YoY
|
1.82B
1.75B – 1.90B
+2.9% YoY
|
| EBIT |
-485.00M
est: 348.84M (-239.0%)
|
561.00M
est: 378.67M (+48.2%)
|
711.00M
est: 371.56M (+91.4%)
|
270.61M
261.45M – 282.11M
-27.2% YoY
|
282.90M
273.31M – 297.62M
+4.5% YoY
|
296.08M
286.06M – 310.11M
+4.7% YoY
|
313.55M
302.93M – 328.40M
+5.9% YoY
|
322.53M
311.61M – 337.81M
+2.9% YoY
|
| Net Income |
2.14B
est: 478.76M (+346.4%)
|
250.00M
est: 803.85M (-68.9%)
|
-1.08B
est: 946.80M (-214.2%)
|
902.16M
746.89M – 1.13B
-4.7% YoY
|
967.56M
830.87M – 1.11B
+7.2% YoY
|
1.07B
1.02B – 1.13B
+10.3% YoY
|
1.29B
1.23B – 1.37B
+21.0% YoY
|
1.23B
1.17B – 1.30B
-4.8% YoY
|
| SGA |
2.53B
est: 2.58B (-2.1%)
|
2.85B
est: 2.96B (-3.7%)
|
2.21B
est: 2.90B (-24.0%)
|
2.11B
2.04B – 2.20B
-27.2% YoY
|
2.21B
2.14B – 2.33B
+4.5% YoY
|
2.31B
2.23B – 2.42B
+4.7% YoY
|
2.45B
2.37B – 2.57B
+5.9% YoY
|
2.52B
2.43B – 2.64B
+2.9% YoY
|
| EPS |
-2.82
est: 1.81 (-255.9%)
|
0.94
est: 3.10 (-69.7%)
|
-4.17
est: 3.65 (-214.2%)
|
3.48
2.88 – 4.36
-4.7% YoY
|
3.73
3.20 – 4.27
+7.2% YoY
|
4.12
3.93 – 4.37
+10.3% YoY
|
4.98
4.76 – 5.28
+21.0% YoY
|
4.74
4.53 – 5.03
-4.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-25 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dimitri de Vreeze | Chief Executive Officer | 3M | male |
| Emmanuel Butstraen | BU President of Perfumery & Beauty and Chief Operating Officer | — | male |
| Jane Sinclair | Advisor to the CEO | — | female |
| Katharina Stenholm | Chief Sustainability Officer | — | female |
| Laetitia Pictet | Chief Legal, Risk & Compliance Officer | — | female |
| Nikeisha van Sleeuwen | Chief Human Resources Officer | — | female |
| Patricia Malarkey | Chief Innovation Officer | — | female |
| Philip Eykerman | Chief Strategy, M&A and Transformation Officer | — | male |
| Ralf Schmeitz | Chief Financial Officer | — | male |
| Dave Huizing | Senior Vice President of Investor Relations | — | male |
| Sarah Reisinger | Chief Science & Research Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for DSFIR.AS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
